Supplementary Figure S1



Supplementary Figure S1. Combination therapy co-targeting CDK4/6 and MEK acts synergistically against MPNST cells in vitro. (A) Contour plot of interaction index (Bliss independence model) for the combination of low doses of palbociclib plus mirdametinib in 26T cells. Red, synergy; green, antagonism. Peak synergy score was 27.9. (B) Representative westerns of 26T and S462 cell lysates following 4hr of cell treatment with vehicle (V), palbociclib (P, 200nM), mirdametinib (M, 200 nM) or the combination (C). P-RB1 (S807/811) is a readout of CDK4/6 inhibition by palbociclib, phosphorylation S807/811 in 26T cells. Right. Imagep-ERK1/2 (T202/Y204) is a readout of MEK inhibition by mirdametinib. (C) Quantification using ImageJ of IF staining intensity for p-RB1 (S807/811) in 26T and S462 cells following treatment as in (B). Results from 3 independent experiments with each dot representing the mean fluorescent value of 10 cells. (D) Representative IF merged images from C. Green, p-RB1 positive; Blue, DAPI stained nuclei. (E) Representative westerns after 24hr of drug treatment in 26T cells show the combination of palbociclib and mirdametinib reduced RB1 J guantification of p-RB1 detection from 3 independent experiments. Mean p-RB1 levels were lowest in combination treated cells although values were not statistically significant. Panels F,G: 26T cell viability assayed by Trypan blue exclusion (F) and senescence measured by senescence associated (SA)- β -galactosidase positivity (G) following treatment for 3 days with the indicated drugs, mirdametinib, 500 nM; palbociclib, 1000 nM, Data were quantified from 3 or more biological repeats. (H) Colony formation assays in 26T cells show synergism between low concentrations of mirdametinib and palbociclib. Left, representative images of the colonies. Right, quantification of percentage area covered by cells from 3 or more experiments. C,F,G,H: Error bars, SEM. P value. One-way ANOVA with Tukey's correction (*, P < 0.05; ***, P < 0.001).